|
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 2,154.40 INR | -1.20% |
|
+0.02% | +5.86% |
| 06-17 | Glenmark Pharmaceuticals Launches Methylene Blue Injection in US | MT |
| 06-11 | Glenmark Pharmaceuticals Unit Launches Acne Treatment Winlevi in European Markets | MT |
| Market Cap | 608B 6.44B 5.66B 5.21B 4.88B 9.14B 9.31B 62.56B 24.23B 300B 24.2B 23.67B 1,041B | P/E 2026 |
44.2x | P/E 2027 * | 26x |
|---|---|---|---|---|---|
| Enterprise Value | 569B 6.03B 5.29B 4.88B 4.56B 8.55B 8.71B 58.52B 22.67B 280B 22.63B 22.14B 974B | EV / Sales 2026 |
3.51x | EV / Sales 2027 * | 3.42x |
| Free-Float |
51.03% | Yield 2026 |
0.12% | Yield 2027 * | 0.27% |
Last Transcript: Glenmark Pharmaceuticals Limited
| 1 day | -1.20% | ||
| 1 week | +0.02% | ||
| Current month | -5.30% | ||
| 1 month | -7.81% | ||
| 3 months | -0.65% | ||
| 6 months | +6.65% | ||
| Current year | +5.86% |
| 1 week | 2,147.8 |  | 2,234.9 |
| 1 month | 2,101 | | 2,400.7 |
| Current year | 1,842 | | 2,474 |
| 1 year | 1,706.8 | | 2,474 |
| 3 years | 644.95 | | 2,474 |
| 5 years | 348.5 | | 2,474 |
| 10 years | 161.65 | | 2,474 |
| Manager | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 56 | 01/01/2000 | |
Anurag Mantri
DFI | Director of Finance/CFO | 54 | 27/05/2025 |
Indrajit Bose
PSD | President | - | 15/09/2023 |
| Director | Title | Age | Since |
|---|---|---|---|
Cherylann Pinto
BRD | Director/Board Member | 58 | - |
| Chairman | 56 | 12/05/2011 | |
| Director/Board Member | 85 | 14/08/2009 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -1.20% | +0.02% | +25.47% | +240.35% | 6.44B | |
| -0.62% | +2.08% | +11.57% | +87.89% | 47.37B | |
| +0.51% | +3.61% | +53.47% | +102.47% | 35.31B | |
| +0.15% | +6.24% | -4.63% | +45.55% | 12.33B | |
| +0.19% | +2.51% | +12.99% | +97.70% | 11.64B | |
| +1.14% | 0.00% | +37.80% | +122.46% | 9.04B | |
| +1.17% | +3.94% | +20.56% | +43.58% | 7.12B | |
| +1.58% | +5.71% | +54.89% | -11.94% | 6.8B | |
| -0.19% | +3.19% | -32.62% | +1.33% | 5.14B | |
| -2.31% | +3.47% | +23.02% | +117.40% | 4.21B | |
| Average | +0.04% | +2.53% | +20.25% | +84.68% | 14.54B | |
| Weighted average by Cap. | +0.03% | +2.03% | +23.97% | +88.48% |
| 2026 | 2027 * | |
|---|---|---|
| Net sales | 153B 1.62B 1.43B 1.31B 1.23B 2.3B 2.35B 15.76B 6.1B 75.48B 6.09B 5.96B 262B | 167B 1.77B 1.55B 1.43B 1.34B 2.51B 2.56B 17.17B 6.65B 82.23B 6.64B 6.49B 286B |
| Net income | 20.53B 218M 191M 176M 165M 309M 314M 2.11B 818M 10.12B 817M 799M 35.17B | 23.11B 245M 215M 198M 185M 348M 354M 2.38B 921M 11.39B 920M 900M 39.6B |
| Net Debt | -39.29B -416M -366M -337M -315M -591M -602M -4.04B -1.57B -19.37B -1.56B -1.53B -67.31B | -37.1B -393M -345M -318M -298M -558M -568M -3.82B -1.48B -18.29B -1.48B -1.44B -63.55B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 25/06/26 | ₹2,154.40 | -1.20% | 348,933 |
| 24/06/26 | ₹2,180.60 | +0.06% | 264,412 |
| 23/06/26 | ₹2,179.40 | -0.57% | 703,100 |
| 22/06/26 | ₹2,191.90 | -0.98% | 354,728 |
| 19/06/26 | ₹2,213.60 | +2.77% | 954,063 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- GLENMARK Stock
Select your edition
All financial news and data tailored to specific country editions
